Regeneron’s antibody cocktail approved by FDA for EbolaAn antibody cocktail from Regeneron has been approved by the FDA as the first treatment for Ebola, offering Share XRegeneron’s antibody cocktail approved by FDA for Ebolahttps://pharmaphorum.com/news/regenerons-antibody-cocktail-approved-by-fda-for-ebola/
Lilly pauses COVID-19 antibody trial after factory hits trouble with FDAEli Lilly has put a clinical trial of its COVID-19 antibody therapy on hold after FDA inspectors found Share XLilly pauses COVID-19 antibody trial after factory hits trouble with FDAhttps://pharmaphorum.com/news/lilly-pauses-covid-19-antibody-trial-after-factory-hits-trouble-with-fda/
Spotlight on COVID-19 antibody therapies after Trump’s recoveryThe spotlight remains on the potential of antibody therapies as a possible way out of the COVID-19 pandemic Share XSpotlight on COVID-19 antibody therapies after Trump’s recoveryhttps://pharmaphorum.com/news/spotlight-on-covid-19-antibody-therapies-after-trumps-recovery/
Regeneron joins Lilly in seeking emergency OK for COVID-19 antibodyRegeneron has followed Eli Lilly in asking the FDA for emergency approval of its COVID-19 antibody therapy, shortly Share XRegeneron joins Lilly in seeking emergency OK for COVID-19 antibodyhttps://pharmaphorum.com/news/regeneron-joins-lilly-in-seeking-emergency-ok-for-covid-19-antibody/
Lilly asks FDA for emergency clearance for COVID-19 antibody therapyEli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing Share XLilly asks FDA for emergency clearance for COVID-19 antibody therapyhttps://pharmaphorum.com/news/lilly-asks-fda-for-emergency-clearance-for-covid-19-antibody-therapy/
GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalGlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting Share XGSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalhttps://pharmaphorum.com/news/gsk-and-vir-expand-covid-19-antibody-trial-after-trumps-treatment-with-regenerons-rival/
Regeneron’s antibody cocktail active against coronavirus, cuts symptomsRegeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test Share XRegeneron’s antibody cocktail active against coronavirus, cuts symptomshttps://pharmaphorum.com/news/regenerons-antibody-cocktail-active-against-coronavirus-cuts-symptoms/
Sanofi/Regeneron’s Libtayo set for new skin cancer useSanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings Share XSanofi/Regeneron’s Libtayo set for new skin cancer usehttps://pharmaphorum.com/news/sanofi-regenerons-libtayo-set-for-new-skin-cancer-use/
Lilly’s antibody therapy cuts hospitalisation rates in COVID-19Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing Share XLilly’s antibody therapy cuts hospitalisation rates in COVID-19https://pharmaphorum.com/news/lilly-says-covid-19-antibody-therapy-cuts-hospitalisation-rates/
